Mirum Pharmaceuticals Inc (MIRM)
24.07
-0.68
(-2.75%)
USD |
NASDAQ |
May 17, 16:00
24.07
0.00 (0.00%)
After-Hours: 20:00
Mirum Pharmaceuticals Research and Development Expense (Quarterly): 32.22M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 32.22M |
| December 31, 2023 | 30.94M |
| September 30, 2023 | 26.12M |
| June 30, 2023 | 22.01M |
| March 31, 2023 | 23.55M |
| December 31, 2022 | 31.10M |
| September 30, 2022 | 26.22M |
| June 30, 2022 | 25.43M |
| March 31, 2022 | 24.09M |
| December 31, 2021 | 27.78M |
| September 30, 2021 | 30.47M |
| Date | Value |
|---|---|
| June 30, 2021 | 35.05M |
| March 31, 2021 | 38.13M |
| December 31, 2020 | 29.73M |
| September 30, 2020 | 15.98M |
| June 30, 2020 | 18.56M |
| March 31, 2020 | 17.34M |
| December 31, 2019 | 14.38M |
| September 30, 2019 | 12.16M |
| June 30, 2019 | 11.59M |
| March 31, 2019 | 4.863M |
| September 30, 2018 | 0.003M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
11.59M
Minimum
Jun 2019
38.13M
Maximum
Mar 2021
24.64M
Average
25.77M
Median
Research and Development Expense (Quarterly) Benchmarks
| Vanda Pharmaceuticals Inc | 21.15M |
| Sarepta Therapeutics Inc | 200.40M |
| Puma Biotechnology Inc | 13.59M |
| Reneo Pharmaceuticals Inc | 4.942M |
| Tharimmune Inc | 1.025M |